Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GQ1010
- Development stage
- Unknown
- Lead developer
- Biohaven
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
GQ1010 is an antibody-drug conjugate (ADC) targeting trophoblast cell surface antigen 2 (TROP2), developed by GeneQuantum Healthcare. It utilizes the proprietary intelligent Ligase-Dependent Conjugation (iLDC) technology platform, which features site-specific enzymatic conjugation to ensure a precise drug-to-antibody ratio. The ADC is composed of a TROP2-targeting monoclonal antibody linked to a next-generation camptothecin analogue, which acts as a Topoisomerase I inhibitor, via a cleavable open-ring linker. Preclinical data suggest that GQ1010 possesses enhanced stability and a broader therapeutic window compared to other TROP2-targeted ADCs. It is currently being evaluated in Phase I/II clinical trials for a variety of advanced solid tumors, including breast, gastric, and gynecological cancers.
- Other names
- dose expansion2
02
Targets
TACSTD2 (Tumor-associated calcium signal transducer 2)
Beyond the preview
Go deeper on GQ1010.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GQ1010.